Sung, H. et al. International most cancers statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 nations. CA: Most cancers J. Clin. 71, 209–249 (2021).
Wu, H.-J. & Chu, P.-Y. Latest discoveries of macromolecule-and cell-based biomarkers and therapeutic implications in breast most cancers. Int. J. Mol. Sci. 22, 636 (2021).
Siegel, R. L., Miller, Okay. D., Fuchs, H. E. & Jemal, A. Most cancers statistics, 2022. CA: Most cancers J. Clin. 72, 7–33 (2022).
Yi, M. et al. Epidemiological tendencies of ladies’s cancers from 1990 to 2019 on the international, regional, and nationwide ranges: a population-based examine. Biomark. Res. 9, 55 (2021).
Lüönd, F., Tiede, S. & Christofori, G. Breast most cancers for instance of tumour heterogeneity and tumour cell plasticity throughout malignant development. Br. J. most cancers 125, 164–175 (2021).
Polyak, Okay. Heterogeneity in breast most cancers. J. Clin. Investig. 121, 3786–3788 (2011).
Sotiriou, C. et al. Breast most cancers classification and prognosis primarily based on gene expression profiles from a population-based examine. Proc. Natl Acad. Sci. 100, 10393–10398 (2003).
Parker, J. S. et al. Supervised danger predictor of breast most cancers primarily based on intrinsic subtypes. J. Clin. Oncol. 27, 1160 (2009).
Sørlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with medical implications. Proc. Natl Acad. Sci. 98, 10869–10874 (2001).
Li, Y. et al. Latest advances in therapeutic methods for triple-negative breast most cancers. J. Hematol. Oncol. 15, 121 (2022).
Bianchini, G., De Angelis, C., Licata, L. & Gianni, L. Remedy panorama of triple-negative breast most cancers – expanded choices, evolving wants. Nat. Rev. Clin. Oncol. 19, 91–113 (2022).
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E. & Gianni, L. Triple-negative breast most cancers: challenges and alternatives of a heterogeneous illness. Nat. Rev. Clin. Oncol. 13, 674–690 (2016).
von Minckwitz, G. et al. Definition and influence of pathologic full response on prognosis after neoadjuvant chemotherapy in varied intrinsic breast most cancers subtypes. J. Clin. Oncol. 30, 1796–1804 (2012).
Chicheportiche, Y., Fossati-Jimack, L., Moll, S., Ibnou-Zekri, N. & Izui, S. Down-regulated expression of TWEAK mRNA in acute and power inflammatory pathologies. Biochem. Biophys. Res. Commun. 279, 162–165 (2000).
Kawakita, T. et al. Purposeful expression of TWEAK in human hepatocellular carcinoma: doable implication in cell proliferation and tumor angiogenesis. Biochem. Biophys. Res. Commun. 318, 726–733 (2004).
Kawakita, T. et al. Purposeful expression of TWEAK in human colonic adenocarcinoma cells. Int. J. Oncol. 26, 87–93 (2005).
Girgenrath, M. et al. TWEAK, through its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J. 25, 5826–5839 (2006).
Lynch, C. N. et al. TWEAK induces angiogenesis and proliferation of endothelial cells. J. Biol. Chem. 274, 8455–8459 (1999).
Chicheportiche, Y. et al. TWEAK, a brand new secreted ligand within the tumor necrosis issue household that weakly induces apoptosis. J. Biol. Chem. 272, 32401–32410 (1997).
Bossen, C. et al. Interactions of tumor necrosis issue (TNF) and TNF receptor members of the family within the mouse and human. J. Biol. Chem. 281, 13964–13971 (2006).
Tran, N. L. et al. The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in superior glial tumors. Am. J. Pathol. 162, 1313–1321 (2003).
Yin, J. et al. AR-regulated TWEAK-FN14 pathway promotes prostate most cancers bone metastasis. Most cancers Res. 74, 4306–4317 (2014).
Chao, D. T. et al. Expression of TweakR in breast most cancers and preclinical exercise of enavatuzumab, a humanized anti-TweakR mAb. J. Most cancers Res. Clin. Oncol. 139, 315–325 (2013).
Cordido, A. et al. TWEAK signaling pathway blockade slows cyst progress and illness development in autosomal dominant polycystic kidney illness. J. Am. Soc. Nephrol. 32, 1913–1932 (2021).
Zhao, Z. et al. TWEAK/Fn14 interactions are instrumental within the pathogenesis of nephritis within the power graft-versus-host mannequin of systemic lupus erythematosus. J. Immunol. 179, 7949–7958 (2007).
Willis, A. L. et al. The fibroblast progress factor-inducible 14 receptor is very expressed in HER2-positive breast tumors and regulates breast most cancers cell invasive capability. Mol. Most cancers Res. 6, 725–734 (2008).
Enwere, E. Okay., LaCasse, E. C., Adam, N. J. & Korneluk, R. G. Position of the TWEAK-Fn14-cIAP1-NF-κB signaling axis within the regulation of myogenesis and muscle homeostasis. Entrance. Immunol. 5, 34 (2014).
Vincent, C. et al. Professional‐inflammatory cytokines TNF‐associated weak inducer of apoptosis (TWEAK) and TNFα induce the mitogen‐activated protein kinase (MAPK)‐dependent expression of sclerostin in human osteoblasts. J. Bone Miner. Res. 24, 1434–1449 (2009).
Zhang, Y., Zeng, W. & Xia, Y. TWEAK/Fn14 axis is a crucial participant in fibrosis. J. Cell. Physiol. 236, 3304–3316 (2021).
Vince, J. E. et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1–TRAF2 complicated to sensitize tumor cells to TNFα. J. Cell Biol. 182, 171–184 (2008).
Cherry, E. M., Lee, D. W., Jung, J. U. & Sitcheran, R. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioma cell invasion by means of induction of NF-kappaB-inducing kinase (NIK) and noncanonical NF-kappaB signaling. Mol. Most cancers 14, 9 (2015).
Kaltschmidt, C. et al. A task for NF-κB in organ particular most cancers and most cancers stem cells. Cancers 11, 655 (2019).
Xie, X. et al. c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast most cancers by means of upregulation of Notch1 through activation of c-Jun. Oncogene 36, 2599–2608 (2017).
Huber, M. A. et al. NF-κB is important for epithelial-mesenchymal transition and metastasis in a mannequin of breast most cancers development. J. Clin. Investig. 114, 569–581 (2004).
Vleugel, M. M., Greijer, A. E., Bos, R., van der Wall, E. & van Diest, P. J. c-Jun activation is related to proliferation and angiogenesis in invasive breast most cancers. Hum. Pathol. 37, 668–674 (2006).
Franco, H. L. et al. Enhancer transcription reveals subtype-specific gene expression packages controlling breast most cancers pathogenesis. Genome Res. 28, 159–170 (2018).
Brown, J. D. et al. NF-kappaB directs dynamic tremendous enhancer formation in irritation and atherogenesis. Mol. Cell. 56, 219–231 (2014).
Han, R. et al. Purposeful CRISPR display identifies AP1-associated enhancer regulating FOXF1 to modulate oncogene-induced senescence. Genome Biol. 19, 118 (2018).
Search engine optimization, J. et al. AP-1 subunits converge promiscuously at enhancers to potentiate transcription. Genome Res. 31, 538–550 (2021).
Michida, H. et al. The variety of transcription components at an enhancer determines switch-like gene expression. Cell Rep. 31, 107724 (2020).
Zhou, H. et al. Growth of human serine protease-based therapeutics focusing on Fn14 and identification of Fn14 as a brand new goal overexpressed in TNBC. Mol. Most cancers Ther. 13, 2688–2705 (2014).
Xu, Okay. et al. Single-cell RNA sequencing reveals cell heterogeneity and transcriptome profile of breast most cancers lymph node metastasis. Oncogenesis 10, 66 (2021).
Li, Y. et al. Non-canonical NF-kappaB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation. Nat. Cell Biol. 17, 1327–1338 (2015).
Dogra, C., Corridor, S. L., Wedhas, N., Linkhart, T. A. & Kumar, A. Fibroblast progress issue inducible 14 (Fn14) is required for the expression of myogenic regulatory components and differentiation of myoblasts into myotubes. Proof for TWEAK-independent capabilities of Fn14 throughout myogenesis. J. Biol. Chem. 282, 15000–15010 (2007).
Dogra, C., Changotra, H., Mohan, S. & Kumar, A. Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis by means of sustained activation of nuclear factor-kappaB and degradation of MyoD protein. J. Biol. Chem. 281, 10327–10336 (2006).
Deka, Okay. & Li, Y. Transcriptional regulation throughout aberrant activation of NF-κB signalling in most cancers. Cells 12, 788 (2023).
Sim, N. & Li, Y. NF-kappaB/p52 augments ETS1 binding genome-wide to advertise glioma development. Commun. Biol. 6, 445 (2023).
Ang, D. A. et al. Aberrant non-canonical NF-kappaB signalling reprograms the epigenome panorama to drive oncogenic transcriptomes in a number of myeloma. Nat. Commun. 15, 2513 (2024).
Di Stefano, V., Wang, B., Parobchak, N., Roche, N. & Rosen, T. RelB/p52-mediated NF-kappaB signaling alters histone acetylation to extend the abundance of corticotropin-releasing hormone in human placenta. Sci. Sign. 8, ra85 (2015).
Raisner, R., Bainer, R., Haverty, P. M., Benedetti, Okay. L. & Gascoigne, Okay. E. Tremendous-enhancer acquisition drives oncogene expression in triple unfavourable breast most cancers. PLoS ONE 15, e0235343 (2020).
Zheng, L. et al. ELK4 promotes the event of gastric most cancers by inducing M2 polarization of macrophages by means of regulation of the KDM5A-PJA2-KSR1 axis. J. Transl. Med. 19, 342 (2021).
Huang, H. et al. Defining super-enhancer panorama in triple-negative breast most cancers by multiomic profiling. Nat. Commun. 12, 2242 (2021).
Xu, J. et al. Subtype-specific 3D genome alteration in acute myeloid leukaemia. Nature 611, 387–398 (2022).
Flavahan, W. A. et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 529, 110–114 (2016).
Cheuk, I. W. et al. ITGAV focusing on as a therapeutic method for remedy of metastatic breast most cancers. Am. J. Most cancers Res. 10, 211–223 (2020).
Marquis, C. et al. Chromosomally unstable tumor cells particularly require KIF18A for proliferation. Nat. Commun. 12, 1213 (2021).
Zhang, H. et al. Epigenetic regulation of NAMPT by NAMPT-AS drives metastatic development in triple-negative breast most cancers. Most cancers Res. 79, 3347–3359 (2019).
Hesari, Z. et al. Down-regulation of NAMPT expression by mir-206 reduces cell survival of breast most cancers cells. Gene 673, 149–158 (2018).
Katsuoka, F. & Yamamoto, M. Small Maf proteins (MafF, MafG, MafK): Historical past, construction and performance. Gene 586, 197–205 (2016).
Xu, X. et al. Structural foundation for reactivating the mutant TERT promoter by cooperative binding of p52 and ETS1. Nat. Commun. 9, 3183 (2018).
Gardell, S. J. et al. Boosting NAD(+) with a small molecule that prompts NAMPT. Nat. Commun. 10, 3241 (2019).
Braidy, N. et al. Position of nicotinamide adenine dinucleotide and associated precursors as therapeutic targets for age-related degenerative illnesses: rationale, biochemistry, pharmacokinetics, and outcomes. Antioxid. Redox Sign. 30, 251–294 (2019).
Fiorillo, M., Ozsvari, B., Sotgia, F. & Lisanti, M. P. Excessive ATP manufacturing fuels most cancers drug resistance and metastasis: implications for mitochondrial ATP depletion remedy. Entrance. Oncol. 11, 740720 (2021).
Mallavarapu, A. & Mitchison, T. Regulated actin cytoskeleton meeting at filopodium ideas controls their extension and retraction. J. Cell Biol. 146, 1097–1106 (1999).
Korn, E. D., Carlier, M. F. & Pantaloni, D. Actin polymerization and ATP hydrolysis. Science 238, 638–644 (1987).
Lin, C. Y. et al. Lively medulloblastoma enhancers reveal subgroup-specific mobile origins. Nature 530, 57–62 (2016).
Zhou, R. W. et al. An area tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma. Nat. Commun. 13, 6041 (2022).
Yu, D. et al. Tremendous-enhancer induced IL-20RA promotes proliferation/metastasis and immune evasion in colorectal most cancers. Entrance. Oncol. 11, 724655 (2021).
Jia, Y. et al. Myeloma-specific superenhancers have an effect on genes of organic and medical relevance in myeloma. Blood Most cancers J. 11, 32 (2021).
Sullivan, W. J. et al. Extracellular matrix transforming regulates glucose metabolism by means of TXNIP destabilization. Cell 175, 117–32.e21 (2018).
Chuang, C. H. et al. Altered mitochondria performance defines a metastatic cell state in lung most cancers and creates an exploitable vulnerability. Most cancers Res. 81, 567–579 (2021).
Lim, S. Okay. et al. Sustained activation of non-canonical NF-kappaB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL. Leukemia 37, 441–452 (2023).
Semenza, G. L. HIF-1: upstream and downstream of most cancers metabolism. Curr. Opin. Genet Dev. 20, 51–56 (2010).
Dang, C. V., Le, A. & Gao, P. MYC-induced most cancers cell vitality metabolism and therapeutic alternatives. Clin. Most cancers Res. 15, 6479–6483 (2009).
Wong, Okay. Okay., Engelman, J. A. & Cantley, L. C. Concentrating on the PI3K signaling pathway in most cancers. Curr. Opin. Genet. Dev. 20, 87–90 (2010).
Shackelford, D. B. & Shaw, R. J. The LKB1-AMPK pathway: metabolism and progress management in tumour suppression. Nat. Rev. Most cancers 9, 563–575 (2009).
Nguyen, T. T. T. et al. HDAC inhibitors elicit metabolic reprogramming by focusing on super-enhancers in glioblastoma fashions. J. Clin. Investig. 130, 3699–3716 (2020).
Tan, B. et al. Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an enzyme important for NAD+ biosynthesis, results in altered carbohydrate metabolism in most cancers cells. J. Biol. Chem. 290, 15812–15824 (2015).
Tan, B. et al. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme important for NAD+ biosynthesis, in human most cancers cells: metabolic foundation and potential medical implications. J. Biol. Chem. 288, 3500–3511 (2013).
Zhou, S. J., Bi, T. Q., Qin, C. X., Yang, X. Q. & Pang, Okay. Expression of NAMPT is related to breast invasive ductal carcinoma growth and prognosis. Oncol. Lett. 15, 6648–6654 (2018).
Gujar, A. D. et al. An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma. Proc. Natl Acad. Sci. USA 113, E8247–E8256 (2016).
Lucena-Cacace, A., Otero-Albiol, D., Jimenez-Garcia, M. P., Munoz-Galvan, S. & Carnero, A. NAMPT is a potent oncogene in colon most cancers development that modulates most cancers stem cell properties and resistance to remedy by means of Sirt1 and PARP. Clin. Most cancers Res. 24, 1202–1215 (2018).
Lucena-Cacace, A., Otero-Albiol, D., Jimenez-Garcia, M. P., Peinado-Serrano, J. & Carnero, A. NAMPT overexpression induces most cancers stemness and defines a novel tumor signature for glioma prognosis. Oncotarget 8, 99514–99530 (2017).
Fiorillo, M., Scatena, C., Naccarato, A. G., Sotgia, F. & Lisanti, M. P. Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP manufacturing and metastasis in vivo, by focusing on the gamma subunit (ATP5F1C) of the ATP synthase. Cell Demise Differ. 28, 2797–2817 (2021).
Zeng, Y. et al. Guiding irregular nuclear morphology on nanopillar arrays for malignancy differentiation in tumor cells. Nano Lett. 22, 7724–7733 (2022).
Bathroom, S. Y. et al. Fatty acid oxidation is a druggable gateway regulating mobile plasticity for driving metastasis in breast most cancers. Sci. Adv. 7, eabh2443 (2021).
Schindelin, J. et al. Fiji: an open-source platform for biological-image evaluation. Nat. Strategies 9, 676–682 (2012).
Jacquemet, G. et al. FiloQuant reveals elevated filopodia density throughout breast most cancers development. J. Cell Biol. 216, 3387–3403 (2017).
Andrew S. FastQC: A top quality management instrument for top throughput sequence information. http://www.bioinformatics.babraham.ac.uk/initiatives/fastqc (2010).
Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a versatile trimmer for Illumina sequence information. Bioinformatics 30, 2114–2120 (2014).
Dobin, A. et al. STAR: ultrafast common RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
Liao, Y., Smyth, G. Okay. & Shi, W. featureCounts: an environment friendly basic goal program for assigning sequence reads to genomic options. Bioinformatics 30, 923–930 (2014).
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq information with DESeq2. Genome Biol. 15, 550 (2014).
Mi, H. et al. Protocol Replace for large-scale genome and gene operate evaluation with the PANTHER classification system (v.14.0). Nat. Protoc. 14, 703–721 (2019).
Thomas, P. D. et al. PANTHER: making genome-scale phylogenetics accessible to all. Protein Sci. 31, 8–22 (2022).
Subramanian, A. et al. Gene set enrichment evaluation: a knowledge-based method for deciphering genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
Mootha, V. Okay. et al. PGC-1alpha-responsive genes concerned in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267–273 (2003).
Zhou, Y. et al. Metascape offers a biologist-oriented useful resource for the evaluation of systems-level datasets. Nat. Commun. 10, 1523 (2019).
Wickham H. ggplot2: Elegant Graphics for Information Evaluation (Cham: Springer Worldwide Publishing: Imprint: Springer, 2016).
Goldman, M. J. et al. Visualizing and deciphering most cancers genomics information through the Xena platform. Nat. Biotechnol. 38, 675–678 (2020).
Hao, Y. et al. Dictionary studying for integrative, multimodal and scalable single-cell evaluation. Nat. Biotechnol. 42, 293–304 (2023).
Aran, D. et al. Reference-based evaluation of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163–172 (2019).
Langmead, B. & Salzberg, S. L. Quick gapped-read alignment with Bowtie 2. Nat. Strategies 9, 357–359 (2012).
Quinlan, A. R. & Corridor, I. M. BEDTools: a versatile suite of utilities for evaluating genomic options. Bioinformatics 26, 841–842 (2010).
Stark S., Brown G. DiffBind: Differential Binding Evaluation of ChIP-Seq Peak Information. 2011.
Ramirez, F. et al. deepTools2: a subsequent technology internet server for deep-sequencing information evaluation. Nucleic Acids Res. 44, W160–W165 (2016).
McLean, C. Y. et al. GREAT improves useful interpretation of cis-regulatory areas. Nat. Biotechnol. 28, 495–501 (2010).
Ramirez, F. et al. Excessive-resolution TADs reveal DNA sequences underlying genome group in flies. Nat. Commun. 9, 189 (2018).
Lopez-Delisle, L. et al. pyGenomeTracks: reproducible plots for multivariate genomic datasets. Bioinformatics 37, 422–423 (2021).
Loven, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320–334 (2013).
Whyte, W. A. et al. Grasp transcription components and mediator set up super-enhancers at key cell id genes. Cell 153, 307–319 (2013).
Corces, M. R. et al. An improved ATAC-seq protocol reduces background and allows interrogation of frozen tissues. Nat. Strategies 14, 959–962 (2017).
Barnett, D. W., Garrison, E. Okay., Quinlan, A. R., Stromberg, M. P. & Marth, G. T. BamTools: a C++ API and toolkit for analyzing and managing BAM recordsdata. Bioinformatics 27, 1691–1692 (2011).
Bentsen, M. et al. ATAC-seq footprinting unravels kinetics of transcription issue binding throughout zygotic genome activation. Nat. Commun. 11, 4267 (2020).
Li H. Aligning sequence reads, clone sequences and meeting contigs with BWA-MEM. arXiv:13033997 [q-bioGN] 2013.
Danecek, P. et al. Twelve years of SAMtools and BCFtools. Gigascience. 2021;10.
Bhattacharyya, S., Chandra, V., Vijayanand, P. & Ay, F. Identification of serious chromatin contacts from HiChIP information by FitHiChIP. Nat. Commun. 10, 4221 (2019).
Lareau, C. A. & Aryee, M. J. diffloop: a computational framework for figuring out and analyzing differential DNA loops from sequencing information. Bioinformatics 34, 672–674 (2018).
